Host Dr. Brian McDonough welcomes Dr. Brian McGowan, Chief Learning Officer of ArcheMedX, Inc, to discuss the educational, logistic, and communicative opportunities for clinicians who utilize both traditional and novel social media networks.
Leveraging Social Media in Clinical Practice
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Host Dr. Brian McDonough welcomes Dr. Brian McGowan, Chief Learning Officer of ArcheMedX, Inc, to discuss the educational, logistic, and communicative opportunities for clinicians who utilize both traditional and novel social media networks.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli
1.00 credits
<p><span data-contrast="none" xml:lang="EN-US">Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli</span> </p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
MinuteCE®
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
1.25 credits
<p>Clinical Conundrums in ARIA: Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies</p>
CME/CE
Impact of Barostim on Heart Failure Hospitalization
<p>Impact of Barostim on Heart Failure Hospitalization</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?